Clinical trial · Interventional
Evaluation of Fapi-pet in Prostate Cancer.
Evaluation of Fapi-pet in Prostate Cancer
NCT05192694CI-TRIAL-00057054FAPIPETPCAunknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The investigators explore the biodistribution of FAPI-PET expression in primary high-risk prostate cancer in men undergoing RALP and eLND and in men with metastatic PCa about to start next generation antiandrogen.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Computed tomography | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- FAPI PET
- description
- Prospective single arm cohort
- interventionNames
- Procedure: Computed tomography
Primary outcomes (1)
- measure
- Positive predictive value on a lesion level
- timeFrame
- through study completion, an average of 1 year
- description
- Positive predictive value of FAPI-PET on a lesion level using histopathology or confirmatory imaging as ground truth
Secondary outcomes (5)
- measure
- Positive predictive value on a patient level
- timeFrame
- through study completion, an average of 1 year
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion Criteria: Men scheduled for radical prostatectomy * Age over 18 years * GG 3-5, cT2-cT3, Nx, M0 prostate cancer * no contraindication to PSMA - or FAPI-PET * willing to undergo study related procedures (imaging and laboratory tests) Men scheduled for novel antiandrogen * Age over 18 years * GG2-5, cT2-4, N0-1, M1 * hormone sensitive or castration resistant prostate cancer Exclusion Criteria: * Not willing or capable to undergo study related procedures
References
Publications (0)
Data not yet available
No reference posted for this study.